Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BEAM-ATG
- Development stage
- Unknown
- Modality
- Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
BEAM-ATG is a high-dose chemotherapy conditioning regimen followed by autologous hematopoietic stem cell transplantation (ASCT). It is composed of the BEAM regimen—carmustine (BCNU), etoposide, cytarabine (Ara-C), and melphalan—supplemented with anti-thymocyte globulin (ATG). This combination is designed to achieve profound immunoablation by utilizing the cytotoxic effects of alkylating agents (carmustine, melphalan), a topoisomerase II inhibitor (etoposide), and an antimetabolite (cytarabine), alongside the T-cell depleting properties of ATG. While BEAM is a standard conditioning protocol for lymphomas, the BEAM-ATG variant is specifically utilized in the treatment of highly active or therapy-refractory autoimmune diseases, most notably multiple sclerosis, to reset the immune system.
- Other names
- BEAM plus ATGBCNU + etoposide + cytarabine + melphalan + anti-thymocyte globulin
02
Targets
DNA polymerase familyTOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on BEAM-ATG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BEAM-ATG.